FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908554080> ?p ?o ?g. }

• W2908554080 endingPage "565" @default.
• W2908554080 startingPage "560" @default.
• W2908554080 abstract "Objective Although the majority of ovarian granulosa cell tumors can be successfully managed with surgery, a subset require chemotherapy for residual and recurrent disease. The benefit of chemotherapy in this population, however, remains controversial. There is therefore interest in the development of more tolerable and effective treatment options for advanced ovarian granulosa cell tumors. We report the use of immunohistochemistry to investigate how biomarkers could inform clinical trials in granulosa cell tumors with an emphasis on emerging androgen antagonistic, immunotherapeutic, and anti-angiogenic approaches. Methods Immunohistochemistry for androgen receptor, the immune markers programmed cell death ligand 1, indoleamine-2,3 dioxygenase, and cluster of differentiation 8, and the vascular marker cluster of differentiation 31 were evaluated on formalin-fixed paraffin-embedded whole tissue sections from 29 cases of adult-type granulosa cell tumors. Results were evaluated with clinicopathologic variables including recurrence. Results 59% of granulosa cell tumors were androgen receptor-positive, suggesting a potential role for anti-androgen therapy in this tumor type. In contrast, the targetable immune modulatory molecules programmed cell death ligand 1 and indoleamine-2,3 dioxygenase were scarcely expressed, with no cases showing tumorous programmed cell death ligand 1 and a single case demonstrating very focal tumorous indoleamine-2,3 dioxygenase staining. A minority of cases expressed programmed cell death ligand 1 in occasional tumor-associated macrophages and indoleamine-2,3 dioxygenase in peritumoral vessels. Tumor-infiltrating cytotoxic T cells were also scarce in granulosa cell tumors, arguing against a significant role for immunotherapy in the absence of additional immunostimulation. Cluster of differentiation 31 immunostaining revealed a range of vascular densities across granulosa cell tumors, and future studies evaluating the role of vascular density as a predictor of response to angiogenesis inhibition are warranted. None of the biomarkers investigated were significantly correlated with recurrence, and the only clinicopathologic feature significantly correlated with outcome was stage at presentation. Conclusions Biomarker data suggest that many ovarian granulosa cell tumors could be candidates for anti-androgen therapy, while the potential role for immunotherapy appears more limited. Vascular density could be useful for identifying optimal candidates for angiogenesis inhibition. Incorporation of these biomarkers into clinical trials could help optimize patient selection." @default.
• W2908554080 created "2019-01-25" @default.
• W2908554080 creator A5002282387 @default.
• W2908554080 creator A5013126901 @default.
• W2908554080 creator A5024048020 @default.
• W2908554080 creator A5024369959 @default.
• W2908554080 creator A5053230314 @default.
• W2908554080 creator A5054372225 @default.
• W2908554080 creator A5059374944 @default.
• W2908554080 date "2019-01-04" @default.
• W2908554080 modified "2023-09-23" @default.
• W2908554080 title "Emerging biomarkers in ovarian granulosa cell tumors" @default.
• W2908554080 cites W1533108534 @default.
• W2908554080 cites W1759669640 @default.
• W2908554080 cites W1979780595 @default.
• W2908554080 cites W1981740467 @default.
• W2908554080 cites W1998345728 @default.
• W2908554080 cites W2044693854 @default.
• W2908554080 cites W2052846984 @default.
• W2908554080 cites W2054475219 @default.
• W2908554080 cites W2063947287 @default.
• W2908554080 cites W2108865532 @default.
• W2908554080 cites W2109485845 @default.
• W2908554080 cites W2118912793 @default.
• W2908554080 cites W2138493972 @default.
• W2908554080 cites W2220882815 @default.
• W2908554080 cites W2300386653 @default.
• W2908554080 cites W2465663488 @default.
• W2908554080 cites W2517074828 @default.
• W2908554080 cites W2564046051 @default.
• W2908554080 cites W2567159391 @default.
• W2908554080 cites W2569252288 @default.
• W2908554080 cites W2615049027 @default.
• W2908554080 cites W2615301036 @default.
• W2908554080 cites W2619427441 @default.
• W2908554080 cites W2621034679 @default.
• W2908554080 cites W2740658377 @default.
• W2908554080 cites W2777785600 @default.
• W2908554080 cites W2788216924 @default.
• W2908554080 cites W2795962379 @default.
• W2908554080 cites W2801169280 @default.
• W2908554080 cites W2803318179 @default.
• W2908554080 doi "https://doi.org/10.1136/ijgc-2018-000065" @default.
• W2908554080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30833441" @default.
• W2908554080 hasPublicationYear "2019" @default.
• W2908554080 type Work @default.
• W2908554080 sameAs 2908554080 @default.
• W2908554080 citedByCount "13" @default.
• W2908554080 countsByYear W29085540802020 @default.
• W2908554080 countsByYear W29085540802021 @default.
• W2908554080 countsByYear W29085540802022 @default.
• W2908554080 countsByYear W29085540802023 @default.
• W2908554080 crossrefType "journal-article" @default.
• W2908554080 hasAuthorship W2908554080A5002282387 @default.
• W2908554080 hasAuthorship W2908554080A5013126901 @default.
• W2908554080 hasAuthorship W2908554080A5024048020 @default.
• W2908554080 hasAuthorship W2908554080A5024369959 @default.
• W2908554080 hasAuthorship W2908554080A5053230314 @default.
• W2908554080 hasAuthorship W2908554080A5054372225 @default.
• W2908554080 hasAuthorship W2908554080A5059374944 @default.
• W2908554080 hasConcept C121608353 @default.
• W2908554080 hasConcept C126322002 @default.
• W2908554080 hasConcept C142724271 @default.
• W2908554080 hasConcept C143998085 @default.
• W2908554080 hasConcept C1491633281 @default.
• W2908554080 hasConcept C190283241 @default.
• W2908554080 hasConcept C204232928 @default.
• W2908554080 hasConcept C2776706248 @default.
• W2908554080 hasConcept C2777203538 @default.
• W2908554080 hasConcept C2778324911 @default.
• W2908554080 hasConcept C2780192828 @default.
• W2908554080 hasConcept C31573885 @default.
• W2908554080 hasConcept C40722700 @default.
• W2908554080 hasConcept C502942594 @default.
• W2908554080 hasConcept C515207424 @default.
• W2908554080 hasConcept C54355233 @default.
• W2908554080 hasConcept C55493867 @default.
• W2908554080 hasConcept C61367390 @default.
• W2908554080 hasConcept C71924100 @default.
• W2908554080 hasConcept C83478079 @default.
• W2908554080 hasConcept C86803240 @default.
• W2908554080 hasConceptScore W2908554080C121608353 @default.
• W2908554080 hasConceptScore W2908554080C126322002 @default.
• W2908554080 hasConceptScore W2908554080C142724271 @default.
• W2908554080 hasConceptScore W2908554080C143998085 @default.
• W2908554080 hasConceptScore W2908554080C1491633281 @default.
• W2908554080 hasConceptScore W2908554080C190283241 @default.
• W2908554080 hasConceptScore W2908554080C204232928 @default.
• W2908554080 hasConceptScore W2908554080C2776706248 @default.
• W2908554080 hasConceptScore W2908554080C2777203538 @default.
• W2908554080 hasConceptScore W2908554080C2778324911 @default.
• W2908554080 hasConceptScore W2908554080C2780192828 @default.
• W2908554080 hasConceptScore W2908554080C31573885 @default.
• W2908554080 hasConceptScore W2908554080C40722700 @default.
• W2908554080 hasConceptScore W2908554080C502942594 @default.
• W2908554080 hasConceptScore W2908554080C515207424 @default.
• W2908554080 hasConceptScore W2908554080C54355233 @default.
• W2908554080 hasConceptScore W2908554080C55493867 @default.

• next